Publication: Ceftriaxone absorption enhancement for noninvasive administration as an alternative to injectable solutions
2
item.page.dc.date.issued
2018-12-01
item.page.dc.type
item.page.dc.identifier.issn
10986596
00664804
00664804
item.page.dc.identifier.doi
item.page.dc.identifier.other
2-s2.0-85057196638
item.page.dc.rights
Mahidol University
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Antimicrobial Agents and Chemotherapy. Vol.62, No.12 (2018)
punsarn.item.page.citation
Boubakar Ba, Karen Gaudin, Amélie Désiré, Thida Phoeung, Marie Hélène Langlois, Charan R. Behl, Joel Unowsky, Indravadan H. Patel, A. Waseem Malick, Melba Gomes, Nicholas White, Tina Kauss Ceftriaxone absorption enhancement for noninvasive administration as an alternative to injectable solutions. Antimicrobial Agents and Chemotherapy. Vol.62, No.12 (2018). doi:10.1128/AAC.01170-18 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/46171
Research Projects
Organizational Units
Authors
Journal Issue
relationships.isThesisOf
item.page.dc.title
Ceftriaxone absorption enhancement for noninvasive administration as an alternative to injectable solutions
item.page.dc.contributor.author
item.page.dc.contributor.other
item.page.dc.description.abstract
Copyright © 2018 American Society for Microbiology. All Rights Reserved. Neonatal sepsis is a major cause of infant mortality in developing countries because of delayed injectable treatment, making it urgent to develop noninjectable formulations that can reduce treatment delays in resource-limited settings. Ceftriaxone, available only for injection, needs absorption enhancers to achieve adequate bioavailability via nonparenteral administration. This article presents all available data on the nonparenteral absorption of ceftriaxone in humans and animals, including unpublished work carried out by F. Hoffmann-La Roche (Roche) in the 1980s and new data from preclinical studies with rabbits, and discusses the importance of these data for the development of noninjectable formulations for noninvasive treatment. The combined results indicate that the rectal absorption of ceftriaxone is feasible and likely to lead to a bioavailable formulation that can reduce treatment delays in neonatal sepsis. A bile salt, chenodeoxycholate sodium salt (Na-CDC), used as an absorption enhancer at a 125-mg dose, together with a 500-mg dose of ceftriaxone provided 24% rectal absorption of ceftriaxone and a maximal plasma concentration of 21 g/ml with good tolerance in human subjects. The rabbit model developed can also be used to screen for the bioavailability of other formulations before assessment in humans.
